Literature DB >> 21437663

Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Emilien Delmont, P Y Jeandel, C Benaïm, E Rosenthal, J G Fuzibet, C Desnuelle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21437663     DOI： 10.1007/s00415-011-5994-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

Review 1.  Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies.

Authors:  Norman Latov; Susanne Renaud
Journal:  J Neurol Sci       Date:  2004-05-15       Impact factor: 3.181

2.  A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Authors:  R C Graham; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

3.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision.

Authors: 
Journal:  J Peripher Nerv Syst       Date:  2010-09       Impact factor: 3.494

4.  Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.

Authors:  Susanne Renaud; Michael Gregor; Peter Fuhr; Delia Lorenz; Günther Deuschl; Alois Gratwohl; Andreas J Steck
Journal:  Muscle Nerve       Date:  2003-05       Impact factor: 3.217

5.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

Authors:  I S Merkies; P I Schmitz; F G van der Meché; P A van Doorn
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

6.  High-dose rituximab and anti-MAG-associated polyneuropathy.

Authors:  S Renaud; P Fuhr; M Gregor; K Schweikert; D Lorenz; C Daniels; G Deuschl; A Gratwohl; A J Steck
Journal:  Neurology       Date:  2006-03-14       Impact factor: 9.910

7.  Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.

Authors:  Luana Benedetti; Chiara Briani; Marina Grandis; Tiziana Vigo; Marco Gobbi; Elisabetta Ghiglione; Marinella Carpo; Dario Cocito; Christina M Caporale; Maria P Sormani; Giovanni L Mancardi; Eduardo Nobile-Orazio; Angelo Schenone
Journal:  J Peripher Nerv Syst       Date:  2007-06       Impact factor: 3.494

8.  Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?

Authors:  Emilien Delmont; Charles Benaïm; Mael Launay; Sabrina Sacconi; Marie-Hélène Soriani; Claude Desnuelle
Journal:  J Neurol       Date:  2009-07-30       Impact factor: 4.849

9.  Rituximab for polyneuropathy with IgM monoclonal gammopathy.

Authors:  J M F Niermeijer; M Eurelings; H L Lokhorst; W-L van der Pol; H Franssen; J H J Wokke; N C Notermans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09       Impact factor: 10.154

10.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

Authors:  Marinos C Dalakas; Goran Rakocevic; Mohammad Salajegheh; James M Dambrosia; Angelika F Hahn; Raghavan Raju; Beverly McElroy
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422
  10 in total
  2 in total

Review 1.  Progress in peripheral nerve disease research in the last two years.

Authors:  Matthew Evans; Hadi Manji
Journal:  J Neurol       Date:  2013-10-25       Impact factor: 4.849

2.  Successful treatment of CANOMAD with IVIg and rituximab.

Authors:  Wolfgang N Löscher; Alexander Woertz; Monika Wallnöfer; Julia V Wanschitz; Gerhard Luef
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.